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Background: Diastolic dysfunction/heart failure in the metabolic syndrome and type 2 diabetes (T2D) is an epi-
demic without evidence-based treatment strategies. While improved glycemic control/insulin sensitivity has
been associated with augmented cardiac function in pharmacologic studies, studies on dietary intervention are
scarce. Low-carbohydrate nutrition (LC) improves postprandial glucose control and insulin resistance more
than standard low-fat diet (LF). We tested the hypothesis, that LC improves cardiac function in overweight-
obese patients with T2D more than LF.
Methods: Twomatched groups of 16 T2Dpatientswithout overt heart disease (52 ± 7 years, BMI 34 ± 6 kg/m2)
were studied in a parallel and partial cross-over design during a 3-week rehabilitation programmewith either LC
or LF followed by 2 weeks LC. Cardiac function was assessed as myocardial velocity during systole and early
diastole (E′) using Doppler tissue imaging and metabolic control before and after a standardised breakfast.
Results: In the parallel groups, both diets induced similar and signiﬁcant reductions of weight, HbA1c and choles-
terol. LC considerably improved insulin resistance, fasting and postmeal triglycerides, blood pressure and diastol-
ic cardiac function E′ (by 0.9 ± 1.4 cm/s, p = 0.023). None of these variables changed on LF, but all of them
improved signiﬁcantly after subsequent LC (E′ by 0.9 ± 1.1 cm/s, p = 0.023). Postprandial intact proinsulin
was unchanged on LF but decreased with subsequent LC (p = 0.032).
Conclusions: These data indicate, that a low-glycaemic/high-protein but not a low-fat/high-carbohydrate
nutrition modulates diastolic dysfunction in overweight T2D patients, improves insulin resistance and may pre-
vent or delay the onset of diabetic cardiomyopathy and the metabolic syndrome.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.Introduction
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land Ltd. Open access under CC BY-NCdiabetes indicates that heart failure may soon reach epidemic propor-
tions [1–3]. Of patients presenting with clinical signs of heart failure,
50% of individuals develop systolic heart failure with reduced ejection
fraction (EF b 50%) HFREF and a similar proportion develops heart
failure with preserved function (HFPEF) (EF N 50%) at initial hospitali-
zation. In contrast to systolic heart failure, there have been no successful
therapeutic interventional clinical trials of HFPEF or of the preceding
diastolic dysfunction [4,5]. Furthermore, assessment of diastolic cardiac
function has been confounded by the semi-quantitative nature of tradi-
tional Doppler echocardiographic methods. LV ﬁlling pressure is a
robust measure of LV diastolic function [6,7] that can now be assessed
non-invasively using Doppler tissue imaging. Although LV diastolic
dysfunction improves with better glycemic control [8–11] and possibly
with exercise, the effects of life style modiﬁcation by dietary interven-
tion remain scarcely known [12]. This is surprising since diet is a pivotal
component in the treatment in type 2 diabetes. Low-carbohydrate diet
normalises metabolic abnormalities in type 2 diabetes and in the meta-
bolic syndrome [13–15] and as suchmay abort or delay themechanisms
promoting diabetic/insulin-resistance cardiomyopathy.-SA license.
Table 1
Baseline characteristics of the study population at T1.
Characteristics Low carb Low fat p T1
No 16 16
Age (years) 52 ± 8 52 ± 7 0.80
Men (no) 5 5 1.0
Body-mass index (kg/m2) 36 ± 6 33 ± 6 0.25
Waist circ. (cm) 116 ± 15 113 ± 15 0.54
Hypertension (%) 81 63 0.25
Hyperlipidemia (%) 50 69 0.30
Smoking (%) 13 24 0.38
Oral glycemic control medications (%) 62 62 1.0
Metformin (%) [mean dose in mg] 62 [1511] 44 [1621] 0.30
Sulfonylurea (%) [mean dose in mg] 38 [3] 31 [5] 0.72
Glitazone (%) [mean dose in mg] 6 [30] 6 [30] 1.0
ACE or AT2 receptor blocker (%) 75 56 0.28
Calcium antagonist (%) 31 38 0.72
HMG Co-A reductase inhibitor (%) 25 19 0.68
HbA1c (%) 6.9 ± 0.8 7.4 ± 1.6 0.23
Glucose (mg/dl) 150 ± 28 158 ± 54 0.62
Insulin (pmol/l) 15 ± 8 10 ± 6 0.062
HOMA-IR 5.6 ± 3.5 3.9 ± 2.6 0.13
Triglyceride/HDL ratio 3.4 ± 1.3 4.0 ± 1.7 0.74
Triglycerides (mg/dl) 150 ± 52 181 ± 78 0.21
Cholesterol (mg/dl) 208 ± 32 228 ± 61 0.25
HDL (mg/dl) 45 ± 8 48 ± 11 0.39
hsCRP (mg/l) 4.0 ± 3.9 4.8 ± 4.5 0.61
Blood pressure systolic (mm Hg) 127 ± 9 130 ± 9 0.45
Blood pressure diastolic (mm Hg) 83 ± 6 85 ± 8 0.49
Rate pressure product (mm Hg/min) 8955 ± 1302 9327 ± 1335 0.43
Maximal exercise capacity (watt) 128 ± 25 128 ± 45 1.0
Data are expressed as mean ± SD, ACE = angiotensin converting enzyme.
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pacity and diastolic cardiac functionwithDoppler tissue imaging during
an inpatient rehabilitation programmewith moderate physical training
to test the hypothesis that in overweight type 2 diabetes patients, a low-
carbohydrate diet exerts signiﬁcantly greater beneﬁcial effects on cardi-
ac function and metabolism than a traditional iso-caloric low-fat/high-
carbohydrate diet [15].
Design and methods
Study design
This study had the prespeciﬁed goal to encourage further research
in metabolic and cardiovascular effects of diets with speciﬁc antithetic
insulinogenic degrees as dynamic determinants of cardiovascular
risk factors and LV diastolic dysfunction. The trial was designed as a
prospective, controlled, matched pair parallel arm with partial cross-
over study for the comparison of two diets in a total 32 overweight pa-
tients with type 2 diabetes. Accordingly, the parallel arms consisted
of 3 week treatment with either a low-carbohydrate or a low-fat/
high-carbohydrate diet, followed in the latter group by two weeks
low-carbohydrate diet in order to check similarity of metabolic and
functional results between groups with small sample size. Analogous
to pharmaceutic interventional studies, the study effects were assessed
both as a result from the 3 interventional meals during the previous day
and the subsequent nightly metabolic homeostasis mechanisms, that is
in the fasting state, and acutely after the interventional testmeal, that is
2 h after the breakfast. Before admission, all patients had lived accord-
ing to the ofﬁcial dietary guideline recommendations [15]. In line with
these, the test meal at baseline was composed of low-fat/high-carbohy-
drate diet, whereas the iso-caloric test meal at the end of any treatment
period was composed in line with the respective interventional diet.
Of the in-patients who consecutively attended a weight loss pro-
gramme at the rehabilitation clinic Ueberruh in Isny, Germany, 32
agreeable individuals were enrolled in the study. The inclusion
criteria were age between 30 and 70 years, overweight (body-mass
index N26 kg/m2) and type 2 diabetes according to the criteria of
the American Diabetes Association [16] on either dietary control or
oral antidiabetic medications. Exclusion criteria were increased LV
size, any history or signs of coronary or valvular heart disease, atrial
ﬁbrillation, serum creatinine N 2 mg/dl and untreated thyroid dys-
function. Patients assigned to the low-carbohydrate group were
matched for age, sex and the use of antidiabetic and antihyperten-
sive medication to the participants in the low-fat group. Baseline de-
mographics and clinical characteristics are listed in Table 1.
Eachpatient providedwritten informed consent to the study. The study
was approved by the Ethical Committee of the Technische Universität
München and is registered in clinical trials gov ID NCT01004757.
Clinical and metabolic parameters, hemodynamics, exercise toler-
ance and cardiac variables were studied at onset (T1) and end (T2) of
the rehabilitation programme with either diet and, additionally in the
low-fat group, after the subsequent two weeks of low-carbohydrate
diet (T3). Change in myocardial diastolic function within a 2–3 weeks
treatment period was considered as primary end-point outcome mea-
sure. Secondary end-point parameters were levels of triglycerides and
of insulin resistance.
Diets, training and medication
The low-fat, restricted calorie diet was based on the recommenda-
tions of the European Association for the Study of Diabetes [15] and
was served in a separate dining room ascribed to this diet alone.
The composition of the diet was aimed at a daily energy intake of
1600–1800 kcal with 55% of calories from carbohydrates of mixed
glycemic index, 20% from low-fat protein and 25% from fat including10–15% of mono-unsaturated fat. The participants were advised to
increase their consumption of low-fat grains, vegetables and fruit.
The non-ketogenic low-carbohydrate diet was served in the dining
room of another building. This diet was based on the recommendations
of Ludwig [13] as described by Heilmeyer [17]. It allowed free access to
vegetable, salads, fruits, protein and plant sources of fat as provided on
the food buffets, which led via the increased satiety by the latter compo-
nents to an average of 1600–1800 kcal calorie intake [17]. A restricted
amount of carbohydrates with low glycemic index was provided with
the goal to achieve 25% of the calorie intake, 30% from protein and
45% from fat including approximately 25% of mono-unsaturated and
10% of polyunsaturated fat.
The training programme was identical for all patients (2 h daily). It
consisted of heart rate controlled aerobic exercise, as determined from
maximal bicycle ergometry with lactate assessment, involving endur-
ance and resistance training. Due to the severely deconditioned status
of the patients, only low intensity training was applicable, so that
energy requirements were increased by 200–400 kcal/day. According
to the study protocol, maintenance of antidiabetic and antihypertensive
medications was intended for all patients and recorded but was adjust-
ed, where indicated, to avoid hypoglycemia or hypotension.
Clinical outcomes
Weight was measured to the nearest 0.1 kg in the patients with-
out their shoes. Exercise capacity was determined by maximal bicy-
cle ergometry. Blood pressure was measured in the sitting patient
after 10 minute rest.
Metabolic parameters were assessed from blood samples by veni-
puncture after a 12-hour fast and 2 h after the subsequent standardised
breakfast (400 kcal) with low-fat composition at T1 and after low-fat
diet at T2, but low-carbohydrate composition after low-carbohydrate
diet at T2 and T3. Serum levels of triglycerides, total cholesterol, high-
density (HDL) and low density lipoprotein (LDL) cholesterol and
glucose were measured in fresh blood samples (ADVIA 2400, Siemens,
Munich, Germany) and glycosylated haemoglobin (HbA1c) using the
G7-HPLC Analyzer (Tosoh Europe NV, Stuttgart, Germany) with intra-
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of serum (−80 °C) were kept until further analysis. Immunoassays
were used for determination of insulin (Chemiluminescence, Invitron
Ltd, Wyastone Leys, UK, CV b 5%), intact proinsulin [18] (TECO®
human Proinsulin ELISA Kit, TECOmedical AG, Sissach, Switzerland,
CV b 5%), nitrotyrosine [19] (Chemiluminescence, Millipore upstate,
Molsheim, Germany, CV b 10%), and OxLDL [20] (Immundiagnostik
AG, Bensheim, Germany, CV 2.5 and 9.4% for intra- and inter-assay
assessment respectively). Insulin resistance was calculated by homeo-
static model of assessment (HOMA-IR) [21] and, additionally, by the tri-
glyceride/HDL ratio [22].
Cardiac function
Two experienced echocardiographers obtained ultrasound data
with a commercially available system (ALOKA Alpha 10, Tokyo) using
traditional echocardiography of cardiac structures, Doppler of the
transmitral inﬂow velocities and Doppler tissue imaging for the quanti-
ﬁcation of cardiac function as systolic (S′) and diastolic (E′) myocardial
velocities in cm/s as previously described [23]. Given the steep decline
of early diastolic myocardial velocity E′ by 1% every year with ageing
in normal people, individual patients were assigned to diastolic dys-
function if the actualmeasured velocity E′was smaller than the calculat-
ed age related cut off level for normal velocity [8].
Statistics
Sample size calculation: Based on increases of E′ in previous inter-
vention studies [11], we anticipated detecting also group differences
in change of E′ of at least 1 cm/s. Assuming less than one half of the
variability in changes of E′ (SD b 0.85), 12 patients per group were nec-
essary to detect this clinically relevant effect size at a two-sided level of
signiﬁcance of 5% with 80% power. Expecting a drop-out proportion of
up to 25%, 16 patients were recruited for each intervention arm.
Statistical analysis was performed using the SPSS version 16.0
software package (SPSS Inc., Chicago, IL). The difference between post-
prandial and fasting values was calculated as postmeal increase (Δ) and
treatment effects as change from baseline. In the low-fat crossover
group, statistical interaction tests were applied to assess possible carry
over effects considering a p value N0.2 as no evidence for interaction.
Signiﬁcant, diet associated, within person changes were assessed by
an ANOVA for repeated measurements and post hoc tests (Bonferroni).
Students't-test or non-parametric tests were used for evaluation
of within person changes in the low-carbohydrate group, and to
assess differences between the matched pair designated groups whereTable 2
Changes by low-carbohydrate and low-fat diet in the parallel groups.
Low carb
Wmax (watt) 10 ± 16*
Rate pressure product (mmHg/min) −933 ± 1104**
Weight (kg) −2.6 ± 3.3**
Waist circ. (cm) −4.4 ± 3.5***
HbA1c (%) −0.3 ± 0.2***
Glucose (mmol/l) fa −17 ± 32**
Glucose (mmol/l) pp −16 ± 32
HOMA-IR −0.9 ± 2.4*
Cholesterol (mmol/l) fa −22 ± 30*
Cholesterol (mmol/l) pp −16 ± 31*
HDL (mmol/l) fa −1 ± 6
HDL (mmol/l) pp 0 ± 5
LDL (mmol/l) fa −14 ± 29(*)
LDL (mmol/l) pp −14 ± 26(*)
Uric acid (μmol/l) −0.5 ± 0.8*
Wmax = maximal exercise capacity, fa = fasting, pp = postprandial; p change = inte
* = p b 0.05, ** = p b 0.01,*** = p b 0.001 and (*) = p b 0.1 ® 0.05 for within person chappropriate. To compare frequency data between independent study
groups, the chi-square test or Fisher's exact test was used as appropri-
ate. Bivariate relationship of quantitative data was assessed by using
Pearson's- or if appropriate, Spearman's correlation coefﬁcient. All sta-
tistical testswere conducted two-sided and a p-value b0.05was consid-
ered to indicate statistical signiﬁcance.
Each patient remained unaware about the assumed cardiac and
metabolic effects of the study diets. The study coordinators and clinical
advisors remained unaware of the outcome data before the end of the
interventions. Measurements and analysis of ultrasound and of meta-
bolic variables were performed by applying single measurement of var-
iables or mean values as speciﬁed in the methods section by staff
blinded to the patients' diet assignment and study protocol.
Results
The baseline data of the parallel treatment groups were comparable
(Table 1). As expected, most patients had increased markers of insulin
resistance. With regard to the primary and secondary outcome mea-
sures, there have been neither clinically relevant nor statistically signif-
icant interaction effects in the cross-over low-fat group.
Within all 32 patients receiving low-carbohydrate diet, diastolic
cardiac function improved in 24 (75%), remained unchanged (absolute
difference less than 0.1 cm/s) in 1 and decreased in 7 (22%). Within
the 16 patients receiving low-fat diet in contrast, only 6 (38%) patients
improved diastolic function, 4 (25%) remained unchanged and 6 (38%)
deteriorated (p = 0.013). Diastolic dysfunction as deﬁned by the age
related normal value of E′ [8] was assigned to 16/32 patients before re-
ceiving low-carbohydrate diet. From these, 13 (81%) improved diastolic
function compared to 5 such improvements (62%) amongst the 8/16
patients with diastolic dysfunction before receiving low-fat diet.
With any diet in the parallel groups, there were similar and signiﬁ-
cant improvements ofweight, long term and fasting glucose and choles-
terol (Table 2). Similarly with both diets, there were neither clinically
relevant nor statistically signiﬁcant changes in LV diameter, wall thick-
ness, atrial size and the traditional parameters of diastolic function, the
mitral inﬂow velocities E and A, their ratio E/A and the LV end-diastolic
pressure calculated as E/E′(data not shown).
The changes frombaselinewere signiﬁcantly different between both
treatment arms with greater beneﬁt from low-carbohydrate diet for
diastolic cardiac function (Fig. 1A), systolic blood pressure (Fig. 1B)
and, as a trend, for waist circumference (Table 2), fasting insulin and
the postmeal ratio triglyceride/HDL (Fig. 2A and B). The following vari-
ables remained nearly unchanged by low-fat diet but signiﬁcantly
improved by low-carbohydrate diet in the parallel group: diastolicLow fat p change P T2
5 ± 11 0.337 0.725
540 ± 1201 0.343 0.075
−1.6 ± 2.2* 0.495 0.301
−2.4 ± 2.3*** 0.069 0.79
−0.3 ± 0.4** 0.953 0.163
−30 ± 29*** 0.127 0.576
−32 ± 73 0.465 0.445
−0.1 ± 1.4 0.277 0.309
−30 ± 43* 0.525 0.445
−34 ± 36** 0.174 0.433
−3 ± 8 0.455 0.709
−3 ± 6 0.238 0.903
−26 ± 21*** 0.229 0.692
−26 ± 20*** 0.156 0.724
−0.9 ± 1.5* 0.341 0. 586
rgroup signiﬁcance for change from baseline; P T2 = intergroup signiﬁcance at T2;
ange from T1 to T2.
Fig. 1. The diet induced changes of cardiac function (panel 1A) and blood pressure (panel 1B) presented asmean and standard deviation. Full rectangle in black = changes induced by the
parallel arm low carbohydrate diet, full rectangle in grey = changes by the respective low fat diet and rectangles with black frames = changes by the subsequent low carbohydrate diet
(2 weeks). The p value of interdiet signiﬁcance is given in numbers. Any signiﬁcant change from the respective baseline is shown as * = p b 0.05, ** = p b 0.01 and *** = p b 0.001.
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capacity and the rate pressure product, as well as markers of insulin
resistance and fasting and postmeal triglycerides (Fig. 2B and C).
Furthermore, these variables also improved by the subsequent low-
carbohydrate diet in the cross-over group (Table 3). Intact proinsulin
remained unchanged with low-fat diet but tended to decrease
after subsequent low-carbohydrate diet fasting and signiﬁcantly de-
creased postmeal (Table 3). Within the cholesterol fractions, the low-
carbohydrate diet induced less though not signiﬁcantly less reduction of
total cholesterol and LDL compared to the parallel low-fat group and sig-
niﬁcantly less reductions from the subsequent low-carbohydrate diet of
only 2 weeks.
In the pooled data, the change of diastolic cardiac function E′
had a signiﬁcant correlation with the change of maximal exercise
capacity (r = +0.503, p b 0.001)(Fig. 3) andwith the change of fasting
glucose (r = +0.299, p = 0.041). In the cross-over group, the change
in E′ had signiﬁcant inverse correlations with baseline postmeal
(r = −0.371, p = 0.043), but not with fasting intact proinsulin, and
furthermore with postmeal nitrotyrosine (r = −0.397, p = 0.030,
Fig. 3) and with the postmeal increase of nitrotyrosine (r = −0.376,
p = 0.030) and with the postmeal (Fig. 4).Taking the respective individual doses of antidiabetic medication at
baseline as 100%, the use of these drugs was decreased in the low-
carbohydrate group by 88% at T2 and by 12% in the parallel low-fat
group but by a further 54% after subsequent low-carbohydrate diet.
Discussion
The main result of the present study in overweight patients with
type 2 diabetes was the improvement in diastolic cardiac function
with low-carbohydrate diet that was associated with increased maxi-
mal exercise capacity and improvements of insulin resistance that
were not achieved by low-fat diet in spite of a similar weight loss. The
strength of the study lies in the assessment of multifactorial variables
potentially impacting on cardiac function including insulin resistance
as well as the postmeal lipid and glucose metabolism when studying
the functional changes induced by two diets of antithetic insulinogenic
degree both in a parallel group and a partial cross over design.
The culprit factor causing diastolic dysfunction and heart failure has
traditionally been ascribed to structural myocardial stiffness. However,
increased evidence points to an additional major role played by insulin
resistance and hyperglycemia [5,11,24,25] as evident from 1. the high
Fig. 2. The same setting for the changes of insulin in panel 1A, the marker of insulin resistance, triglycerides/HDL in panel 2B, and triglycerides in panel 2C.
15H. von Bibra et al. / IJC Metabolic & Endocrine 2 (2014) 11–18prevalence of diastolic dysfunction in patientswithmetabolic syndrome
[8,26], 2. the description of an insulin resistance cardiomyopathy or
diabetic cardiomyopathy [27,28] and 3. the ﬁrst interventional trialsreporting improved diastolic function with medical therapy that
improves glycemic control or insulin resistance [8–11]. Surprisingly,
the effects of life style interventions on diastolic function have been
Table 3
Diet induced changes by cross-over from low-fat to low-carbohydrate.
Low fat Low carbohydrate p ANOVA p change
Wmax (watt) 5 ± 11 2 ± 7⁎ 0.053 0.425
Weight (kg) −1.6 ± 2.2⁎ 1.7 ± 1.4 ⁎⁎⁎### 0.000 0.84
Waist circumference (cm) −2.4 ± 2.3⁎⁎ −2.3 ± 1.3 ⁎⁎⁎### 0.000 0.84
HbA1c (%) −0.3 ± 0.4⁎⁎ −0.3 ± 0.3 ⁎⁎### 0.000 0.96
Glucose (mmol/l) fa −30 ± 29⁎⁎ −3 ± 27⁎⁎ 0.001 0.009
pp −32 ± 73 -11 ± 45 0.029 0.37
Cholesterol (mmol/l) fa −30 ± 43(⁎) 3 ± 22 0.047 0.010
pp −34 ± 36⁎ −6 ± 25 0.004 0.004
HDL (mmol/l) fa −2.7 ± 7.5 3 ± 6 0.125 0.045
pp −2.5 ± 6.3 3 ± 4 0.077 0.006
LDL (mmol/l) fa −26 ± 21⁎⁎ −1 ± 18 0.001 0.001
pp −26 ± 20⁎⁎⁎ −1 ± 17 0.000 0.002
Intact proinsulin (μmol/l) fa −1 ± 8 −6 ± 10⁎⁎(#) 0.021 0.445
pp −4 ± 15 −8 ± 9⁎⁎# 0.004 0.44
Nitrotyrosine (μg/ml) fa 58 ± 180 8 ± 138 0.265 0.38
pp 16 ± 169 10 ± 147 0.813 0.90
Wmax = maximal exercise capacity, fa = fasting, pp = postprandial. Signiﬁcant p values are shown in bold letters. p ANOVA for repeated measures (T1, T2 and T3), post hoc test
Bonferroni.
# = p b 0.05.
## =p b 0.01.
### = p b 0.001.
(#)= p b 0.1 – N 0.05 for intragroup signiﬁcance of low-carbohydrate nutrition at T3 vs. T2.
⁎ = p b 0.05.
⁎⁎ = p b 0.01.
⁎⁎⁎ = p b 0.001 for comparison with T1 either at T2 after low-fat diet or at T3 after both successive diets,p change = interdiet signiﬁcance for change from each respective baseline.
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gard to nutrition, focussed on very strict caloric reduction [12], that is
known to result in limited patient compliance.
Dietary intervention, however, should be of greater interest because
of its potential for lowering public health costs compared to pharmaco-
logic therapy and reducing recurrent hospital admissions for heart
failure in patients with metabolic syndrome [5,8,26–28,32] sinceFig. 3. In the pooled data, the correlation for the diet-induced change of diastolic cardiac
function E′ with the change of exercise capacity is positive and signiﬁcant. Full black
dots = low carbohydrate diet in the parallel group, full grey dots = low fat diet in the re-
spective group and black circles the subsequent cross over low carbohydrate diet of the
latter group.the underlying insulin resistance may be modulated by more appropri-
ate composition of nutrition. This may change the paradigm for
recommending low-fat/high-carbohydrate diet [15] that has been
shown to be less beneﬁcial on all manifestations of the metabolic
syndrome as compared to low-carbohydrate/high-protein nutrition
[13,34,35]. In addition, the low-carbohydrate/high-protein diet is asso-
ciated with a concomitant N50% reduction in antidiabetic oral or insulinFig. 4. In the pooled data of the cross-over group, the correlation for the diet-induced
change of diastolic cardiac function E′with the postmeal increase of nitrotyrosine at base-
line is inverse and signiﬁcant. Black dots indicate the changes after low-fat and black cir-
cles those after the subsequent low-carbohydrate diet.
17H. von Bibra et al. / IJC Metabolic & Endocrine 2 (2014) 11–18medication [14,17] suggesting a successful approach to underlying
pathophysiological mechanisms that potentially also promote diabetic/
insulin-resistance cardiomyopathy.
Diastolic function E' may translate into daily life performance as
demonstrated by the positive correlation between the diet induced
changes of E' and of exercise capacity in the present study population
that has not been shown before. However, E' has been shown not only
to be more sensitive than systolic function for detecting ischemic and
othermyocardial metabolic derangements, but also in detecting revers-
ibility of diastolic dysfunction [8]. In the present study, improved myo-
cardial energy substrate utilisation is likely to be involved given the
critical limitations of myocardial energy availability in the diabetic
heart [32]. Factors contributing to limited myocardial energy availability
include down-regulated perfusion from endothelial dysfunction, im-
paired intracellular bioenergetics and reduced cardiac efﬁciency [28].
All of the above are based on potentially reversible metabolic derange-
ments such as altered insulin signalling, post-meal oxidative stress and
increased cytokine activity [23,25,32–35].
Theoretically, regular exercise training and a low-fat diet should
improve glycemic control and reduce body weight and, accordingly, de-
crease insulin resistance that may translate into improvement of blood
pressure and cardiac function [31]. However, this potential functional
beneﬁt may be counteracted by high carbohydrate related ﬂuctuations
in the postmeal levels of insulin, triglycerides and oxidative stress aggra-
vating impaired insulin signalling, endothelial dysfunction and, thus,
myocardial dysfunction [25,28,32]. This has been demonstrated after a
single high carbohydrate test meal in overweight, diabetic patients [33].
This mechanism was also suggested by the 6/16 patients with the low-
fat diet associated deterioration in left ventricular function and possibly
also in earlier studies on exercise based life style changeswith adherence
to the recommended low-fat/high-carbohydrate nutrition [29–31].
The metabolic differences between the two diets related to the
speciﬁc post-prandial carbohydrate metabolism [14,34,35]. Low-
carbohydrate nutrition was demonstrated to reduce insulin levels and
insulin resistance that was associated with less of a burden for the
beta cell as shown by the respective reduction of intact proinsulin.
This conﬁrms the potential of adequate nutrition to prevent or delay de-
terioration or development of type 2 diabetes. Furthermore, fasting and
postmeal triglyceride levels decreased by almost 30% in spite of the
higher relative percentage of fat intake, demonstrating that serum
lipid levels in overweight type 2 diabetes patients do not passively mir-
ror the amount of consumed fat. Given the myocardial triacylglycerol
accumulation in diabetic cardiomyopathy [36], such a substantial reduc-
tion of dyslipidemia may be expected to augment cardiac function as
conﬁrmed by our results. The key role of postprandial glucose control
in overweight type 2 diabetes with insulin resistance is corroborated
by our observation that the change in diastolic function correlated in-
versely withmarkers of postmeal but not with fasting insulin resistance
or oxidative stress.
The present data have great potential for the dietary prevention
of diabetes and cardiovascular risk analogous to the reduced risk of
diabetes, hypertension and adverse cardiac events associated with the
α-glucosidase inhibitor acarbose [37] that is also effective by reducing
postprandial hyperglycemia and hyperinsulinemia. A low-carbohydrate
non-restricted-calorie diet may be optimal for those who cannot adhere
to a restricted-calorie diet [35].
Our data with short term dietary intervention are concordant
with long term studies demonstrating the beneﬁcial effects of low-
carbohydrate diets on all features of the metabolic syndrome [14,35,38].
This suggests, that causal pathophysiologic mechanisms of the metabolic
syndrome are successfullymet by this dietary prevention of postprandial
dysmetabolism implicating the potential to prevent or delay the onset of
diastolic heart failure and cardiovascular disease [2,8,24,32,39]. These
ﬁndings are further corroborated by the associated reduction of
antihyperglycemic medication by 54–88% that is similar to previous re-
ports [14,17,40].Limitations
The following aspects of our study, however, deserve critical review.
The partial cross over design allowed only 2 additional weeks with low-
carbohydrate nutrition; this was due to ﬁnancial restrictions by the
management of the rehabilitation clinic andmayhaveweakened the re-
spective changes of the studied variables, nevertheless, the similarity of
these changes to those in the parallel group excludes bias in patient se-
lection in small samples. The small sample size may be regarded as a
limitation, although the signiﬁcant associations in this small study
group underscore the relevance of the ﬁndings. For the sake of homoge-
neity in the study population, participants with overt cardiovascular
disease had been excluded. However, this does not limit the relevance
of our ﬁndings, because the overall relationship of glucose metabolism
and insulin resistance with diastolic function has been shown to play a
role independent of coronary artery disease and heart failure asmediat-
ing factors [4,9,32]. The design of the study did not allow us to elucidate
and differentiate the mechanisms underlying the changes in diastolic
function in overweight diabetics; likely the moderate reduction of sys-
tolic and diastolic blood pressure has contributed but cannot account
for the whole range of functional cardiac improvement considering
the normal range of blood pressure at baseline. Finally, the ﬁndings in
this study warrant conﬁrmation in future randomized studies to deter-
mine if these early beneﬁcial cardiac effects are sustained long term as
suggested by the respective long term effects on metabolism and car-
diovascular risk factors [14,15,35,38].
This is the ﬁrst study to demonstrate that dietary control of insulin
resistance and postmeal glucose levels by a moderate restriction of car-
bohydrate intake improves diastolic dysfunction in obese patients with
type 2 diabetes. This study shows that dietarymodulation is the corner-
stone of treatment of type 2 diabetes and the metabolic syndrome and
has potential cost-savings in reducing expensive hospital admissions
by delaying or preventing the onset of diastolic heart failure based on
diabetic/insulin resistant cardiomyopathy. Moreover, the ﬁndings sup-
port the hypothesis that by normalizing the underlying pathophysiolog-
ical mechanisms, the metabolic syndromemay be improved in all of its
manifestations.
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